Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis
NCT04586010Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of fenebrutinib in multiple sclerosis (MS), sponsored by Roche. Started Mar 2021; status: active, not recruiting.
02
Drugs
fenebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04586010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586010.